Spirea, a biotech company spun out from the University of Cambridge, is committed to delivering the next generation of antibody drug conjugate (ADC) therapeutics to revolutionise cancer treatment and improve the lives of patients.
Status | Active |
Website | https://www.spirea.co.uk/ |
Category | Biotech |
Modality | Biological & Cell |
Therapautics Area | Oncology |
Investment Portfolio | Fund Investment |